c19early.org COVID-19 treatment researchCOVID-19 treatments

Supplementary Data — Vitamin B12 for COVID-19: real-time meta-analysis of 4 studies

@CovidAnalysis, November 2026, Version 2V2 (V1 2023)

Vitamin B12 COVID-19 outcomes

c19early.org
November 2026
StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Jang78%0.22 · 0.04–1.33no recov.1/610/13ECMO patients Erfani (RCT)75%0.25 · 0.03–2.01ICU1/174/17 Erfani (RCT)−1%1.01 · 0.72–1.41hosp. time17 (n)17 (n) Bejan34%0.66 · 0.30–1.44death617 (n)8,589 (n) Bejan35%0.65 · 0.31–1.36ventilation618 (n)8,611 (n) Bejan16%0.84 · 0.44–1.60ICU625 (n)8,642 (n) Bejan10%0.90 · 0.61–1.32hosp.678 (n)9,070 (n) Nimer24%0.76 · 0.52–1.10hosp.35/395184/1,753 Nimer27%0.73 · 0.51–1.02severe case40/395220/1,753
00.511.52+
Rotate screen for more detailsIncrease width for more details
← Vitamin B12
reduces riskVitamin B12
increases risk →
Fig. S1. All outcomes.
Loading..
Fig. S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.